AMPK can better inhibit the growth and metabolism of tumor cells, thereby reducing the abnormal metabolism and immunosuppression level at TIME, and at the same time, enhance the activity and infiltration of CD8+T cells in TIME, leading to enhance the immunotherapeutic effect of the tumor, enhancing the negative regulatory effect of macrophages and dendritic cells (DC cells), inhibiting the immunosuppressive effect of TIME, and ultimately promoting the immunotherapeutic efficacy of a tumor. The gene discussed is PRKAA1; the disease is neoplasm.